A detailed history of Clark Estates Inc transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Clark Estates Inc holds 208,250 shares of CPRX stock, worth $4.52 Million. This represents 1.08% of its overall portfolio holdings.

Number of Shares
208,250
Previous 224,950 7.42%
Holding current value
$4.52 Million
Previous $3.48 Million 18.83%
% of portfolio
1.08%
Previous 0.89%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$15.19 - $21.35 $253,673 - $356,545
-16,700 Reduced 7.42%
208,250 $4.14 Million
Q2 2024

Aug 08, 2024

SELL
$14.68 - $16.92 $88,814 - $102,366
-6,050 Reduced 2.62%
224,950 $3.48 Million
Q1 2024

May 07, 2024

BUY
$13.18 - $17.11 $441,530 - $573,185
33,500 Added 16.96%
231,000 $3.68 Million
Q4 2023

Feb 12, 2024

BUY
$11.78 - $17.29 $111,910 - $164,255
9,500 Added 5.05%
197,500 $3.32 Million
Q3 2023

Nov 13, 2023

BUY
$11.69 - $15.02 $2.2 Million - $2.82 Million
188,000 New
188,000 $2.2 Million

Others Institutions Holding CPRX

About CATALYST PHARMACEUTICALS, INC.


  • Ticker CPRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 102,820,000
  • Market Cap $2.23B
  • Description
  • Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...
More about CPRX
Track This Portfolio

Track Clark Estates Inc Portfolio

Follow Clark Estates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Clark Estates Inc, based on Form 13F filings with the SEC.

News

Stay updated on Clark Estates Inc with notifications on news.